U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H34O4
Molecular Weight 314.4602
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIBUTYL SEBACATE

SMILES

CCCCOC(=O)CCCCCCCCC(=O)OCCCC

InChI

InChIKey=PYGXAGIECVVIOZ-UHFFFAOYSA-N
InChI=1S/C18H34O4/c1-3-5-15-21-17(19)13-11-9-7-8-10-12-14-18(20)22-16-6-4-2/h3-16H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H34O4
Molecular Weight 314.4602
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Dibutyl sebacate (DBS) is an organic chemical which is mainly used as a plasticizer in the production of such plastics as cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, polyvinyl butyral, polyvinyl chloride, polystyrene, and many synthetic rubbers and other plastics. It is used for plastics in the food packaging industry, in medical devices, and for pharmaceutical applications. It is classified as mildly toxic by ingestion in humans and has shown experimental reproductive effects in animals; however, it is also approved by the US-FDA as a food additive to be used with the minimum quantity needed to produce the intended effect.

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
Dibutyl sebacate was selected as a plasticiser in the formulation of sustained-release matrix tablets. Dibutyl sebacate was added to a dichloromethane/EC solution and subsequently spray-dried, or was mixed as a liquid with EC powder. Hydrated tablets were evaluated by frequency sweep and creep rheological tests to correlate the results with drug release.
Route of Administration: Oral
In Vitro Use Guide
Dibutyl Sebacate (DBS) was diluted with dimethyl sulfoxide. Estrogenic activity was measured using a yeast two-hybrid system and a fluorescence polarization system within a concentration range of 10^-7 to 10^-3 M. Yeast strain Y190 was transformed with the pGBT9-receptors and pGAD424-coactivators using the lithium acetate method, and an S9 hepatic microsomal fraction was used to implement the mediating influence of metabolic bioactivation. DBS was tested for its ability to displaceflourescent non-steroid estrogen from the estrogen receptor. A threshold of B-galactosidase activity above 0.1, greater than 50% inhibition and a 1.5 fold increase in cell growth over controls was considered estrogenic activity. DBS showed the weakest cytotoxicity among tested compounds and an IC50 value for B-galactosidase that was higher than the applicable measurement range.
Substance Class Chemical
Record UNII
4W5IH7FLNY
Record Status Validated (UNII)
Record Version